MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Generation Bio Co. Deferred Revenue 2011-2026 | GBIO
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Generation Bio Co.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 M | 12.9 M | 12.9 M |
Quarterly Deferred Revenue Generation Bio Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 149 K | 1.51 M | 2.11 M | 10.6 M | 11.5 M | 13.6 M | 12.8 M | 12.9 M | 12 M | 8.26 M | 5.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.6 M | 149 K | 8.28 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
563 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B |  France |
 |
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
3.2 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
1.73 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.78 | 4.83 % | $ 9.09 B |  Australia |
 |
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
339 K | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Fate Therapeutics
FATE
|
381 K | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
248 K | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
8.5 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
934 K | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Galectin Therapeutics
GALT
|
200 K | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Gilead Sciences
GILD
|
202 M | $ 138.34 | -1.28 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
538 K | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
26 M | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
300 M | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
20 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
1.96 M | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
30.1 M | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
4.84 M | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
1.75 M | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |